New features in combined therapy of human papillomavirus infection


  • Л. С. Осипова NMAPE named after P.L. Shupik Clinical Hospital “Feofaniya” Medical department of the State Administration of Affairs, Ukraine
  • А. А. Суханова NMAPE named after P.L. Shupik, Ukraine
  • Е. И. Соколова NMAPE named after P.L. Shupik, Ukraine


immunomodulation, inosine pranobex, the immune system, human papillomavirus infection, Groprinozin


The article presents the results of studying the eff ectiveness and experience with antiviral and immunomodulating drug Groprinozin (inosine pranobex) in treatment of human papillomavirus infection in women. The results of immunological studies. Based on the studies found that the inclusion of Groprinozin in the complex therapy of these patients contributes to immunological reactivity, improve the clinical course of the disease, a signifi cant reduction in relapses.

Author Biographies

Л. С. Осипова, NMAPE named after P.L. Shupik Clinical Hospital “Feofaniya” Medical department of the State Administration of Affairs

PhD, associate professor at the Department of Clinical Laboratorial Immunology and Allergology;

Head of Laboratory of Clinical Immunology;

Chief specialist in immunology

А. А. Суханова, NMAPE named after P.L. Shupik

MD, professor at the Department of Obstetrics, Gynecology and Reproductology

Е. И. Соколова, NMAPE named after P.L. Shupik

Postgraduate student at the Department of Obstetrics, Gynecology and Reproductology


  1. Antonov, V.G., Kozlov, V.K. “Pathogenesis of cancer diseases. Cytoplasmic and molecular genetics mechanisms of immune resistance of malignant cells.” Cytokines and inflammation 3.2 (2004): 23–33.
  2. Akhmatova, A.N. Clinical and immunological criteria for the prognosis of the persistent current of papillomavirus infection in women with chronic cervicitis. Thesis abstract for PhD degree. Chelyabinsk (2010): 23 p.
  3. Egorova, V.N., Babachenko, I.V., Degtyareva, M.V., Popovich, A.M. Interleukin-2: clinical experience in pediatric practice. Sankt Petersburg. Publishing house “New alternative polygraphy” (2008): 44 p.
  4. Sexually transmitted infections. Ed. by V.A. Akovbyan, V.I. Prokhorenkov, E.V. Sokolovskiy. A manual for the system of postgraduate professional education of doctors. Moscow. Media Sphere (2007): 448–513.
  5. Abramovskyh, O.S. Immunological aspects of the pathology of the cervix, associated with papillomavirus infection. Thesis abstract for MD degree. Chelyabinsk (2011): 32 p.
  6. Ershov, F.I., Kiselev, O.I. Interferons and their inducers (from molecules to drugs). Moscow. GEOTAR-Media (2005).
  7. Ershov, F.I., Romantsov, M.G. Medicines used in viral diseases. A guide for doctors. Moscow. GEOTAR-Media (2007).
  8. Ershov, V.A., Narvskaya, O.V. Background processes and neoplasia of the cervical epithelium. Sankt Petersburg. The human (2007): 79 p.
  9. Dmitriev, G.A., Bitkina, O.A. Papillomavirus infection. Moscow. The medical book (2006): 76 p.
  10. Kiselev, V.I. Human papilloma viruses in the growth of cervical cancer. Moscow: Company “Dimitrade Graphic Group” (2004): 180 p.
  11. Kiselev, V.I., Kiselev, O.I. Human papilloma viruses in the growth of cervical cancer. St. Petersburg-Moscow. Roza Mira (2003).
  12. Mohanty, K.C., Scott, C.S. “Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study.” Genitourin Med 62 (1986): 352–55.
  13. Rogovskaya, S.I. Papillomavirus infection in women and cervical pathology: to help a practicing doctor. 2nd edition. Moscow. GEOTAR-Media (2008).
  14. Rogovskaya, S.I., Prilepskaya, V.N. “Optimization of the treatment of chronic cervicitis with isoprinosine.” Gynecology 8.1 (2006): 4–7.
  15. Rusakevich, R.S., Grishanovich, R.V. “Systemic functional approach to the diagnosis and treatment of viral changes in cervix.” Siberian Oncological Journal 3.45 (2011).
  16. Prilepskaya V.N., Sukhikh, G.T., Rogovskaya, S.I., et al. “Optimization of treatment of genital papillomavirus infection in women.” Obstetrics and gynecology 3 (2007): 72–4.
  17. Semenov, D.M., Zanko, S.N., Dmitrachenko, T.I. Papillomavirus infection (clinical and pathogenetic features, treatment, prevention). Teaching-methodical manual. St. Petersburg. Dialect (2008): 83 p.
  18. Chumakov, P.M. “Protein p53 and its universal functions in a multicellular organism.” Successes of Biological Chemistry 47 (2007): 3–52.
  19. Bais, A.G., Beckmann, I.J., Lindemans, J., et al. “A shift to a peripheral Th2 type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions.” J Clin Pathol 58.10 (2005): 1096–1100.
  20. Benton, С., Shahidullah. H., Hunter, J.A.A. “Human papillomavirus in the immunosuppressed.” Papillomavirus Rep 2 (1992): 23–6.
  21. Georgala, S., Katoulis, A.C., Befon, A., et al. “Oral inosiplex in the treatment of cervical condylomata acuminata: a randomized placebocontrolled trial.” Br J Obstet Gynaecol 113.9 (2006): 1088–91.
  22. Jenkins, M., Chiriva-Internati, M., Mirandola, L., et al. “Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.” Int Rev Immunol 31.1 (2012): 3–21.
  23. Kodner, C.M., Nasraty, S. “Management of genital warts.” Am Fam Physician 70.12 (2004): 2335–42.
  24. Ji, P., Jiang, H., Rekhtman, K., et al. “Rb-Skp2-p27 Pathway Mediates Acute Cell Cycle Inhibition by Rb and Is Retained in a Partial-Penetrance Rb Mutant.” Mollecular cell 16.1 (2004): 47–58.
  25. Münger, К. “Human papillomavirus immortalization and transformation functions.” Review Virus Research 89.2 (2002): 213–28.
  26. Ohnishi, H., Kosuzume, H., Inaba, H., et al. “Mechanism of host defense suppression induced by viral infection: mode of action of inosiplex as an antiviral agent.” Infect and Immun 38.1 (1982): 243–50.
  27. Tay, S.K. “Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study.” Int J STD AIDS 7.4 (1996): 276–80.
  28. Centers for diseases control anf prevention. Guidelines 2002 for treatment of sexually transmitted diseases. CDC. Atlanta. USA (2002): 400 p.
  29. Russomano, F., Reis, A., Camargo, M., et al. “Efficacy in treatment of subclinical cervical HPV infections without CIN. Systemic review.” Sao Paulo Med J 118.4 (2000): 109–15.
  30. Franco, E.L., Villa, L.L., Richardson, H., et al. “Epidemiology of Cervical Human Papillomavirus Infection.” In: Franco E. & Mosonego J., editors. New Developments in Cervical Cancer Screening and prevention. Oxford: Blackwell Science (1997): 14–22.
  31. Critchlow, C.W., Koutsky, L.A. “Epidemiology of human papillomavirus infection.” In: Mindel A., editor. Genital warts. Human papillomavirus infection. London. Edward Arnold (1995): 53–81.
  32. Linhares, R.E., Rebello, M.A., Nozawa, C.M. “Effect of isoprinosine on rotavirus replication in vitro.” Braz J Med Biol Res 2 (1996): 219–22.
  33. Ludicke, F., Stalberg, A., Vassilokos, P., et al. “High and intermediate risk human papillomavirus infectionin sexually active adolescent females.” J Pediatr Adolesc Gynecol 14.4 (2001): 171–4.
  34. Divizia, M., Venuti, A., Degener, A.M., et al. “Methisoprinol – effect on the replication cycle of human hepatitis A virus.” Microbiologica 4 (1992): 323–8.
  35. De Simone, C., Famularo, G., Tzantzoglou, S., et al. “Inosine pranobex in the treatment of HIV infection: a review.” J Immunopharmacol 1 (1991): 19–27.
  36. Femiano, F., Gombos, F., Scully, C. “Oral proliferative verrucous leukoplakia (PVL); open trial of surgery compared with combined therapy using surgery and methisoprinol in papillomavirusrelated PVL.” J Oral Maxillofac Surg 4 (2001): 318–22.
  37. Davidson-Parker, J., Dinsmore, W., Khan, M.N., et al. “Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study.” Genitourin Med 64.6 (1988): 383–6.
  38. Von Knebel Doeberitz V. “New markers for cervical dysplasia to visulise the genomic chaos created by aberrant oncogenic papilomavirus infection.” Eur J Cancer 38 (2002): 2229–42.



How to Cite

Осипова, Л. С., Суханова, А. А., & Соколова, Е. И. (2018). New features in combined therapy of human papillomavirus infection. REPRODUCTIVE ENDOCRINOLOGY, (39), 68–75. Retrieved from



Inflammatory diseases